GLPG3667

Phase 2Small molecule

GGalapagos NV

GLPG3667 is one of 109 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

PsoriasisActive, not recruiting

DermatomyositisActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

PsoriasisPhase 1

Active, not recruiting

DermatomyositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Stelara

Johnson & Johnson

Preclinical

37 3

Taltz

Eli Lilly

Preclinical

20 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

Raptiva

Roche

Preclinical

10 8

Remicade

OOrganon and Co

Preclinical

20 9

Siliq

BBausch Health Americas, Inc.

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interaction2 trials

Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects

Completed·GGalapagos NV·Phase 1·NCT05272683·14 enrolled

Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects

Completed·GGalapagos NV·Phase 1·NCT04736927·14 enrolled

Systemic Lupus Erythematosus1 trial

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Active, not recruiting·GGalapagos NV·Phase 2·NCT05856448·186 enrolled

Dermatomyositis1 trial

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

Active, not recruiting·GGalapagos NV·Phase 2·NCT05695950·40 enrolled

Psoriasis1 trial

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Completed·GGalapagos NV·Phase 1·NCT04594928·30 enrolled

Adult Subject1 trial

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Completed·GGalapagos NV·Phase 1·NCT04976270·23 enrolled

2 more indications

Oral1 trial

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Completed·GGalapagos NV·Phase 1·NCT04097938·52 enrolled

Unspecified1 trial

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

Completed·GGalapagos NV·Phase 1·NCT05335447·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for GLPG3667. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLPG3667 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLPG3667. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Galapagos NV company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGalapagos NV

GLPG3667

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interaction2 trials

Systemic Lupus Erythematosus1 trial

Dermatomyositis1 trial

Psoriasis1 trial

Adult Subject1 trial

Oral1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News